| Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics. | |
| | |
MedLine Citation:
|
PMID: 20531951 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: Evaluate the effect of lipopenic and hypotensive treatment on homocysteine levels. METHODS: We recruited 145 type 2 diabetics and 130 control subjects. Thirty-seven diabetics had no complications, 54 had microvascular complications and 54 had macrovascular complications. We determined the parameters homocysteine of lipid, vitamin B12, triglycerides, and folates for all subjects. Associated treatments used one or more of the following drugs, statin, fibrate, angiotensin-converting enzyme inhibitor and beta-blockers. RESULTS: Hyperhomocysteinemia was present in 35.6% of patients. Diabetics had elevated serum levels of triglycerides (P < 0.001), homocysteine (P < 0.01), folates (P < 0.01) and vitamin B12 (P < 0.001). A strong association was found between type 2 diabetes and hyperhomocysteinemia (P < 0.001). Diabetics with associated treatment had elevated homocysteine, vitamin B12 and folate levels when compared to diabetes-free controls. For diabetics with macrovascular complications, we found significant differences in homocysteine (P = 0.010) and folate (P = 0.014) between those taking associated drugs and those who did not. For diabetics with microvascular complications, a significant difference was found in folate only (P = 0.012). CONCLUSION: Drugs used for hypertension and hyperlipidemia may have an effect on homocysteine levels, for this reason the interaction between drug action and homocysteine levels should be taken into consideration. |
| | |
Authors:
|
Mabrouka El Oudi; Zied Aouni; Haroun Ouertani; Chakib Mazigh; Salem Machghoul |
Publication Detail:
|
Type: Journal Article Date: 2010-05-25 |
Journal Detail:
|
Title: Vascular health and risk management Volume: 6 ISSN: 1178-2048 ISO Abbreviation: Vasc Health Risk Manag Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-06-10 Completed Date: 2010-08-24 Revised Date: 2010-09-30 |
Medline Journal Info:
|
Nlm Unique ID: 101273479 Medline TA: Vasc Health Risk Manag Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 327-32 Citation Subset: IM |
Affiliation:
|
Département de biochimie, Service d'endocrinologie, Hôpital militaire de Tunis, 1008 Montfleury, Tunisie. doc_mo@ymail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antihypertensive Agents / adverse effects, therapeutic use* Antilipemic Agents / adverse effects, therapeutic use* Biological Markers / blood Case-Control Studies Chi-Square Distribution Diabetes Mellitus, Type 2 / blood, complications, drug therapy* Female Folic Acid / blood Homocysteine / blood* Humans Hyperhomocysteinemia / blood*, etiology Male Middle Aged Odds Ratio Risk Assessment Risk Factors Time Factors Treatment Outcome Triglycerides / blood Vitamin B 12 / blood |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Antilipemic Agents; 0/Biological Markers; 0/Triglycerides; 454-28-4/Homocysteine; 59-30-3/Folic Acid; 68-19-9/Vitamin B 12 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimizing blood pressure control through the use of fixed combinations.
Next Document: Should we screen for masked hypertension in patient with vascular disease?